Alkermes To Fly Solo On Vivitrol After Cephalon’s Departure
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech cites need to educate physicians about long-acting injectable for alcohol dependence.
You may also be interested in...
Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak
The CNS specialist outlined long-term commercial prospects for four drugs in its “emerging blockbuster” portfolio during an investor day presentation. The company also unveiled a new clinical candidate, a drug for the treatment of Alzheimer’s agitation.
With Alkermes’ Transition Well Under Way, Commercial Expansion Is Next
As Alkermes advances its proprietary pipeline, the company is beginning to build its commercial organization ahead of what will be the launch of its first wholly owned drug since it took the marketing reins with Vivitrol in 2008.
For Alkermes' Vivitrol, FDA Not Viewing Trial Results From Russia With Love
Underreporting of adverse events may be a Russian "cultural norm," the agency says in a briefing document released in advance of an advisory panel review of Alkermes' Vivitrol (naltrexone) for opioid dependence.